ASX - By Stock
|
NTI |
Re:
Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint
|
|
reon1
|
6 |
1.9K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
6
|
1.9K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene to present at 2024 Cholangiocarcinoma Conference
|
|
reon1
|
216 |
92K |
4 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
216
|
92K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
reon1
|
48 |
12K |
0 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
12K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
reon1
|
48 |
12K |
3 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
12K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
1 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
14 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
14
|
|
ASX - By Stock
|
EUR |
Re:
Ann: Notification of Expiry of Options and Options Offer
|
|
reon1
|
145 |
29K |
3 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
145
|
29K
|
3
|
|
ASX - By Stock
|
OLY |
Re:
Ann: Drilling Intersects 2.3% Li2O at Cadillac Lithium Project
|
|
reon1
|
14 |
3.0K |
3 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
14
|
3.0K
|
3
|
|
ASX - By Stock
|
OLY |
Re:
Ann: Drilling Intersects 2.3% Li2O at Cadillac Lithium Project
|
|
reon1
|
14 |
3.0K |
5 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
14
|
3.0K
|
5
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
reon1
|
23 |
5.9K |
2 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
5.9K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
reon1
|
23 |
5.9K |
3 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
5.9K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
reon1
|
23 |
5.9K |
4 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
5.9K
|
4
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
reon1
|
41 |
9.1K |
2 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
41
|
9.1K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
reon1
|
23 |
5.9K |
1 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
5.9K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
10 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
10
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
5 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
5 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
11 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
reon1
|
13K |
6.2M |
16 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
13K
|
6.2M
|
16
|
|
ASX - By Stock
|
EMD |
Re:
Ann: Emyria Expands Specialist AP Team - First Female for MDMA-AT
|
|
reon1
|
5 |
1.3K |
2 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
5
|
1.3K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
reon1
|
22K |
11M |
15 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
22K
|
11M
|
15
|
|
ASX - By Stock
|
LRV |
Re:
Ann: Pause in Trading
|
|
reon1
|
20 |
4.6K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
20
|
4.6K
|
0
|
|
ASX - By Stock
|
LRV |
Re:
Ann: Pause in Trading
|
|
reon1
|
20 |
4.6K |
1 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
20
|
4.6K
|
1
|
|
ASX - By Stock
|
LRV |
Re:
Ann: Pause in Trading
|
|
reon1
|
20 |
4.6K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
20
|
4.6K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene to present at 2024 Cholangiocarcinoma Conference
|
|
reon1
|
216 |
92K |
22 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
216
|
92K
|
22
|
|
ASX - By Stock
|
AS2 |
Re:
Ann: Askari Delivers Corporate Strategy Update for African Focus
|
|
reon1
|
18 |
3.6K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
18
|
3.6K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
reon1
|
680 |
269K |
1 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
680
|
269K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
WBT competitors
|
|
reon1
|
43 |
20K |
0 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
43
|
20K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
WBT competitors
|
|
reon1
|
43 |
20K |
1 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
43
|
20K
|
1
|
|
ASX - By Stock
|
SOM |
Re:
Ann: Trading Halt
|
|
reon1
|
17 |
4.0K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
17
|
4.0K
|
0
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Board Changes
|
|
reon1
|
1 |
757 |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1
|
757
|
1
|
|
ASX - By Stock
|
AGN |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation For HIE
|
|
reon1
|
18 |
5.0K |
6 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
18
|
5.0K
|
6
|
|
ASX - By Stock
|
AGN |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation For HIE
|
|
reon1
|
18 |
5.0K |
5 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
18
|
5.0K
|
5
|
|
ASX - By Stock
|
AS2 |
Re:
Ann: Askari Raises $1.6M to Expand Exploration Activity in Africa
|
|
reon1
|
16 |
3.7K |
4 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
16
|
3.7K
|
4
|
|
ASX - By Stock
|
ALA |
Re:
Ann: ALA-101 and onCARlytics collaboration update
|
|
reon1
|
62 |
26K |
5 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
62
|
26K
|
5
|
|
ASX - By Stock
|
ALA |
Re:
Ann: ALA-101 and onCARlytics collaboration update
|
|
reon1
|
62 |
26K |
8 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
62
|
26K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
reon1
|
39 |
8.0K |
4 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.0K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
reon1
|
39 |
8.0K |
5 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.0K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
|
|
reon1
|
147 |
63K |
10 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
147
|
63K
|
10
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
|
|
reon1
|
147 |
63K |
14 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
147
|
63K
|
14
|
|
ASX - By Stock
|
EMV |
Re:
Ann: Board Changes
|
|
reon1
|
17 |
5.1K |
10 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
17
|
5.1K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
reon1
|
422 |
145K |
3 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
422
|
145K
|
3
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
reon1
|
349 |
152K |
2 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
349
|
152K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
reon1
|
349 |
152K |
4 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
349
|
152K
|
4
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
reon1
|
349 |
152K |
2 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
349
|
152K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
reon1
|
422 |
145K |
2 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
422
|
145K
|
2
|
|
ASX - By Stock
|
AS2 |
Re:
Ann: Askari Metals - Focused African Clean Energy - Presentation
|
|
reon1
|
22 |
3.8K |
3 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
22
|
3.8K
|
3
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301
|
|
reon1
|
2 |
594 |
5 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
2
|
594
|
5
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
reon1
|
31K |
15M |
3 |
28/02/24 |
28/02/24 |
Charts
|
31K
|
15M
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
reon1
|
680 |
269K |
8 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
680
|
269K
|
8
|
|